Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Amylyx Pharmaceuticals, Inc.AMLX-0.991.301.312.73-84.43%-79.23%50.24$3.65-$15.7336,805$3.765

Detail of Amylyx Pharmaceuticals, Inc.

 
CEO
Mr. Joshua B. Cohen
Employees
237
Industry
Biotechnology
Sector
Healthcare
Market cap
$256M

Company details

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$196.48M
Cost of goods (CoG)
-$133.99M
Gross profit (GP)
$62.49M
Operating expense (OE)
-$275.58M
Research and development (R&D)
-$126.11M
General and administrative (G&A)
-$149.48M
Operating income (OI)
-$213.09M
Other income expense (OIE)
-$60.25M
Pretax income (PI)
-$257.48M
Tax (TAX)
-$1.99M
Net income (NI)
-$259.47M
Amylyx Pharmaceuticals, Inc.
AMLX • XNGS • US
$3.765
-11.37 (-75.20%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$3.81
Margin profit
-132.05%
52 week low
$1.62
52 week high
$19.57
50-day simple moving average
$3.58
200-day simple moving average
$3.65
Percent held by insiders
14.30%
Percent held by institutions
82.46%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
AMLX -75.74%
eps change
AMLX -445.16%